Hematopoietic Stem Cell Transplant in Devic's Disease
Summary
This study is designed to examine whether treating Devic's disease patients with high dose cyclophosphamide together with rabbit antithymocyte globulin (rATG)/rituximab (drugs which reduce the function of the immune system), followed by return of previously collected patient's stem cells will result in improvement in Devic's disease. Stem cells are undeveloped cells that have the capacity to grow into mature blood cells, which normally circulate in the blood stream. The purpose of the intense chemotherapy is to destroy the cells in patient's immune system, which may be causing his/her disease. The purpose of the stem cell infusion is to produce a normal immune system that will no longer attack patient's body. The purpose of study is to examine the safety and efficacy of this treatment. The drugs used in this study treatment are drugs for commonly used for immune suppression.
Timeline
- Start
- 2009-10-10
- Primary completion
- 2018-11
- Completion
- 2018-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 50 mg/kg | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 500 mg | — |
| Subject | rATG | Protein / enzyme biologic | 1.5 mg/kg | — |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | — | — |
| Background | G-CSF | Protein / enzyme biologic | 5 ug/kg | — |
| Background | G-CSF | Protein / enzyme biologic | 10 ug/kg | — |
| Background | Methylprednisolone | Other / unclassified | — | — |